上腺素与上腺素作为感染性休克儿童的初始治疗方法
Matthew A Eisenberg1,2,3, Nathan Georgette1,2,3, Alexandra H Baker1,2,3
1Division of Emergency Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts.
JAMA network open
|April 11, 2025
概括
在儿科的败血性休克中,上腺素作为第一个血管活性剂与与上腺素相比的30天死亡率更高有关,尽管主要的脏不良事件没有不同. 需要进一步的研究来证实诺阿基尼林是首选的第一线治疗.
科学领域:
- 儿科重症监护医学 儿科重症监护医学
- 儿童传染病 儿童传染病
- 儿科急救医学 儿科急救医学
背景情况:
- 儿童的感染性休克管理缺乏标准化的初始血管活性剂.
- 在选择为儿科败血症休克治疗的第一种血管活性药物时,实践中存在差异.
研究的目的:
- 为了比较上腺素与上腺素作为患有败血性休克儿童的初始血管活性剂的结果.
- 调查最初选择血管活性剂与重大脏不良事件 (MAKE30) 和死亡率之间的关联.
主要方法:
- 在四级护理儿童医院进行的回顾性队列研究.
- 倾向性得分匹配用于分析231名患有感染性休克的儿童 (1个月至18岁) 的数据.
- 评估的结果包括MAKE30,30天死亡率和其他二次临床终点.
主要成果:
- 开始63.6%的患者服用了上腺素,而36.4%的患者服用了北上腺素.
- 在加权后,在上腺素和上腺素组之间没有观察到MAKE30的显著差异.
- 经过倾向匹配后,上腺素与较高的30天死亡率 (3.7%) 相比,上腺素 (0%) 与较高的30天死亡率有关.
结论:
- 在儿科败血症休克中初始使用上腺素与30天死亡率的增加有关,但不是MAKE30.
- 上腺素可能是一个更安全的第一线血管活性剂,但需要进一步的前性研究.
- 研究结果表明,需要重新评估当前的指导方针,用于初始的血管活性剂选择在儿科败血症休克.
相关概念视频
01:30Adrenergic Agonists: Therapeutic Uses
689
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
689
01:28Adrenergic Agonists: Mixed-Action Agents
630
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
630
01:26Adrenergic Receptors: β Subtype
1.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.4K
01:30Adrenergic Agonists: Direct-Acting Agents
1.3K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.3K
01:18Adrenergic Agonists: Therapeutic Classification
640
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
640
01:27Adrenergic Neurons: Neurotransmission
3.2K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.2K